Two posters presented at AMCP 2026 found low dry eye disease (DED) treatment uptake and frequent discontinuation among ...

John Barkett, MBA, discusses recent regulatory proposals to make massive health plan price files more usable. Price ...

As cell and gene therapies (CGTs) continue to receive regulatory approvals at an accelerating pace, health care institutions ...

Reproxalap was found to be safe to take in patients diagnosed with dry eye disease (DED), as no serious treatment-emergent adverse events (TEAEs) were reported in patients taking the medication. These ...

Tim Church, MD, PhD, MPH, explains that access to care—not willpower—is the central barrier to GLP-1 use, and says employer ...

Genome-first analyses in UK Biobank and All of Us support RBM20 as an arrhythmogenic DCM gene, with an etiologic fraction of ...

Shawn Davis, MD, discusses what access and policy changes are needed to close the coverage gap. Glucagon-like peptide-1 ...

Amy Leader, DrPH, MPH, explains that trust is key to clinical trial enrollment at an Institute for Value-Based Medicine event in Philadelphia. 259 Prospect Plains Rd, Bldg H Cranbury, NJ 08512 ...

Amy Leader, DrPH, MPH, explains that trust is key to clinical trial enrollment at an Institute for Value-Based Medicine event in Philadelphia. Leader said many large cancer centers are working more ...

An Excel-based actuarial model (1 million lives; 49% eligible; 10% treated) estimated semaglutide coverage could be ...

Environmental triggers were reported by 69.4% of patients, most commonly water/handwashing, chemical irritants, contact ...

Sparsentan received full FDA approval for FSGS in patients aged 8–75 years, addressing a rare, progressive glomerulopathy ...